Prosecution Insights
Last updated: April 19, 2026
Application No. 18/197,150

N-ALKYL SUBSTITUTED CYCLIC AND OLIGOMERIC PERHYDRIDOSILAZANES, METHODS OF PREPARATION THEREOF, AND SILICON NITRIDE FILMS FORMED THEREFROM

Non-Final OA §102§103§112
Filed
May 15, 2023
Examiner
BAKSHI, PANCHAM
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Gelest Inc.
OA Round
3 (Non-Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
2y 5m
To Grant
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allow Rate
873 granted / 1132 resolved
+17.1% vs TC avg
Strong +30% interview lift
Without
With
+30.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
77 currently pending
Career history
1209
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
32.0%
-8.0% vs TC avg
§102
23.0%
-17.0% vs TC avg
§112
27.0%
-13.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1132 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 08/04/2025 has been entered. Status of the Application Claims 1-4 and 6-12 are pending, of which Claims 6-11 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-4 and 12 are under current examination. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim(s) 1, 2 and 12 are rejected under 35 U.S.C. 112(b), as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention (see M.P.E.P 608.01 (k)). Claims 1 and 2 are indefinite because the claim recites R as branched alkyl group having two to about 10 carbon atoms. This is because an alkyl with 2 carbon atoms cannot be a branched alkyl group. Since claim 12 doesn’t cure the above deficiency, claim 12 is also indefinite. Appropriate correction/explanation required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1 and 2 are rejected under 35 U.S.C. 102(a)(1) and 102 (a)(2) as being anticipated by Blum (US 5008422). Determining the scope and contents of the prior art Blum discloses oligomeric N-alkyl perhydridosilazane along with synthesis, comprising reacting a primary alkyl amine with a dihalosilane at a temperature of less than 0C : PNG media_image1.png 668 570 media_image1.png Greyscale Formula 3, encompasses elected species and compound of claim 4 and 5, when a=2 and R=1-6C, lower alkyl PNG media_image2.png 597 560 media_image2.png Greyscale (entire application, especially abstract, Col 4, 8-10, 21). The cited prior art further discloses example of compounds along with their synthesis with R=Me or Et (col 4, 21, Examples 1 (R=Et) and 2 (R=Me) (reads on all limitations of claims 1-2): PNG media_image3.png 368 606 media_image3.png Greyscale PNG media_image4.png 570 555 media_image4.png Greyscale PNG media_image5.png 711 563 media_image5.png Greyscale The cited prior art further discloses using compounds in making ceramic material, fiber coating and binders. (abstract). Since the cited prior art reads on all the limitations of the instant claims 1-2, these claims are anticipated. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-4, 12 and elected species are rejected under 35 U.S.C. 103 as being unpatentable over Blum (US 5008422). Determining the scope and contents of the prior art Blum discloses oligomeric N-alkyl perhydridosilazane along with synthesis, comprising reacting a primary alkyl amine with a dihalosilane at a temperature of less than 0C : PNG media_image1.png 668 570 media_image1.png Greyscale Formula 3, encompass elected species and compound of claim 4 and 5, when a=2 and R=1-6C, lower alkyl PNG media_image2.png 597 560 media_image2.png Greyscale (entire application, especially abstract, Col 4, 8-10, 21). The cited prior art further discloses example of compounds along with their synthesis with R=Me or Et (col 4, 21, Examples 1 (R=Et) and 2 (R=Me) and a=2: PNG media_image3.png 368 606 media_image3.png Greyscale PNG media_image4.png 570 555 media_image4.png Greyscale PNG media_image5.png 711 563 media_image5.png Greyscale The cited prior art further discloses using compounds in making ceramic material, fiber coating and binders (abstract). Ascertaining the differences between the prior art and the claims at issue Blum teaches genus that encompasses the elected species of the instant claims and also discloses species encompassed by the genus of the instant claims. The cited prior art further discloses using compounds in making ceramic material, fiber coating and binders. Thus, the teaching of the cited prior art is different with respect to R group of the elected species, isopropyl (elected species) vs 1-6 C alkyl with examples of R as Me and Et. Resolving the level of ordinary skill in the pertinent art With regard to the above difference-Since examples of species (R=Me and Et) and subgenus (R=1-6C alkyl) taught by the cited prior art are structurally similar to that claimed, it would have been obvious to a person of ordinary skill in the art to choose the claimed species or subgenus from the genus, based on the reasonable expectation that structurally similar species usually have similar properties. See, e.g., Dillon, 919 F.2d at 693, 696, 16 USPQ2d at 1901, 1904. See also Deuel, 51 F.3d at 1558, 34 USPQ2d at 1214. “Structural relationships may provide the requisite motivation or suggestion to modify known compounds to obtain new compounds. For example, a prior art compound may suggest its homologs because homologs often have similar properties and therefore chemists of ordinary skill would ordinarily contemplate making them to try to obtain compounds with improved properties.” Importantly, in this case, the cited prior art discloses homolog example (Ethyl) of the elected species (isopropyl) and also suggest that they have similar properties and therefore chemists of ordinary skill would contemplate making them to try to obtain compounds with improved properties. Further, a person of ordinary skill in the art would have been motivated to try different substituents on N atom and Si as suggested by the cited prior art to arrive at compounds useful in making ceramic material, fiber coating and binders. Thus, the cited prior art meets limitations of the instant claims. Considering objective evidence present in the application indicating obviousness or nonobviousness To establish a prima facie case of obviousness, three basic criteria must be met: (1) the prior art reference must teach or suggest all the claim limitations; (2) there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference or to combine reference teachings; and (3) there must be a reasonable expectation of success; and (MPEP § 2143). In this case, Blum teaches genus which encompass the elected species and examples of species encompassed by the genus of the instant claims. In this case at least prong (E) “Obvious to try” – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success would apply. The rationale to support a conclusion that the claim would have been obvious is that “a person of ordinary skill has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipated success, it is likely that product [was] not of innovation but of ordinary skill and common sense. In that instance the fact that a combination was obvious to try might show that it was obvious under § 103.”KSR, 550 U.S. at ___, 82 USPQ2d at 1397. If any of these findings cannot be made, then this rationale cannot be used to support a conclusion that the claim would have been obvious to one of ordinary skill in the art. Further, there is a reasonable expectation of success that the compound structurally similar and encompassed by the genus of the cited prior art may be useful in in making ceramic material, fiber coating and binders. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention by taking the advantage of the teaching of the above cited references and to make the instantly claimed compound with a reasonable expectation of success. Response to Arguments Applicant’s remarks, affidavit and amendment, as filed on 08/04/2025, have been fully considered but not found persuasive. Applicant argued over rejection under 102 that the instant claims recite R as branched with 2-10 C atoms, different from the cited prior art. This is not found persuasive because R as 2 carbon atoms alkyl group cannot be branched and the cited prior art teaches R as 2 carbon atom ethyl group. Applicant argued over rejection that the instant claims recite R as branched with 2-10 C atoms, different from the cited prior art. PNG media_image6.png 540 989 media_image6.png Greyscale This is not found persuasive because (1) R as 2 carbon atoms alkyl group cannot be branched and the cited prior art teaches example of compound and its synthesis, wherein R= 2 carbon atom ethyl group with a=2 and b=0, same compound as in the instant claims. Applicant argued over previously submitted affidavit and technical advantage of thermodynamic properties of the instant compound, which would not be expected based on the cited prior art. Affidavit provided that presently claimed invention is directed to perhydridocyclic silazane of formula I and argued over about differences of the compound when R in such compound is branched vs linear. PNG media_image7.png 683 837 media_image7.png Greyscale This is not found persuasive and the instant claims stand rejected. This is because the instant claims are not drawn to a cyclic perhydridocyclic silazane of formula I but to an open chain perhydridosilazane of formula 4. See paragraphs from the instant specification, as filed. Thus, data presented in affidavit is irrelevant to the instant claims and not persuasive. PNG media_image8.png 595 820 media_image8.png Greyscale PNG media_image9.png 541 840 media_image9.png Greyscale PNG media_image10.png 647 836 media_image10.png Greyscale PNG media_image11.png 438 823 media_image11.png Greyscale Applicant’s presented argument that cyclic perhydridocyclic silazane of formula I and perhydridosilazane of formula 4 share same chemical structure, i.e. Si-N bond and presented data cyclic perhydridocyclic silazane of formula I and argued about differences of the compound when R in perhydridocyclic silazane is branched vs linear. This is not found persuasive and the instant claims stand rejected. This is because, contrary to applicant’s arguments, perhydridocyclic silazane of formula I and perhydridosilazane of formula 4 does not share same structure. If these are same structure, applicant may amend the claim to perhydridocyclic silazane of formula I instead of perhydridosilazane of formula 4. Further, perhydridocyclic silazane of formula I is a cyclic compound and not an open chain perhydridosilazane of formula 4. Thus, again do not share same structure. Also, see paragraphs from the instant specification, as filed. PNG media_image8.png 595 820 media_image8.png Greyscale PNG media_image9.png 541 840 media_image9.png Greyscale PNG media_image10.png 647 836 media_image10.png Greyscale PNG media_image11.png 438 823 media_image11.png Greyscale Thus, the data presented in affidavit and argued is irrelevant to the instant claims and not persuasive. Just because two compounds contain Si-N bond do not make these compounds as same compounds. Having an ethyl group in two different compounds, does not make two different compounds as same compounds. For example, cyclic hexane and n-hexane are not same compounds. Applicant then acknowledges that compounds of the affidavit are in fact different from the instant claims but argues that it is still unexpected results as thermodynamic behavior of cyclic silazane are equally applicable to non-cyclic silazane PNG media_image12.png 742 982 media_image12.png Greyscale PNG media_image13.png 564 975 media_image13.png Greyscale This is not found persuasive and the instant claims stand rejected under 102 and 103. This is because (1) An argument by the applicant is not evidence unless it is an admission, in which case, an examiner may use the admission in making a rejection. See MPEP § 2129 and § 2144.03 for a discussion of admissions as prior art. Arguments presented by applicant cannot take the place of evidence in the record. See In re De Blauwe, 736 F.2d 699, 705, 222 USPQ 191, 196 (Fed. Cir. 1984); In re Schulze, 346 F.2d 600, 602, 145 USPQ 716, 718 (CCPA 1965); In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997) ("An assertion of what seems to follow from common experience is just attorney argument and not the kind of factual evidence that is required to rebut a prima facie case of obviousness."). See MPEP § 716.01(c) for examples of applicant statements which are not evidence and which must be supported by an appropriate affidavit or declaration; (2) just recognizing thermodynamic properties of compound of the cited prior art does not render claims nonobvious. Mere recognition of latent properties in the prior art does not render nonobvious an otherwise known invention. In re Wiseman, 596 F.2d 1019, 201 USPQ 658 (CCPA 1979) (Claims were directed to grooved carbon disc brakes wherein the grooves were provided to vent steam or vapor during a braking action. A prior art reference taught noncarbon disc brakes which were grooved for the purpose of cooling the faces of the braking members and eliminating dust. The court held the prior art references when combined would overcome the problems of dust and overheating solved by the prior art and would inherently overcome the steam or vapor cause of the problem relied upon for patentability by applicants. Granting a patent on the discovery of an unknown but inherent function (here venting steam or vapor) "would remove from the public that which is in the public domain by virtue of its inclusion in, or obviousness from, the prior art." 596 F.2d at 1022, 201 USPQ at 661.); In re Baxter Travenol Labs., 952 F.2d 388, 21 USPQ2d 1281 (Fed. Cir. 1991) (Appellant argued that the presence of DEHP as the plasticizer in a blood collection bag unexpectedly suppressed hemolysis and therefore rebutted any prima facie showing of obviousness. However, the closest prior art utilizing a DEHP plasticized blood collection bag inherently achieved same result, although this fact was unknown in the prior art.). "The fact that appellant has recognized another advantage which would flow naturally from following the suggestion of the prior art cannot be the basis for patentability when the differences would otherwise be obvious." Ex parte Obiaya, 227 USPQ 58, 60 (Bd. Pat. App. & Inter. 1985) (The prior art taught combustion fluid analyzers which used labyrinth heaters to maintain the samples at a uniform temperature. Although appellant showed that an unexpectedly shorter response time was obtained when a labyrinth heater was employed, the Board held this advantage would flow naturally from following the suggestion of the prior art.). See also Lantech Inc. v. Kaufman Co. of Ohio Inc., 878 F.2d 1446, 12 USPQ2d 1076, 1077 (Fed. Cir. 1989), cert. denied, 493 U.S. 1058 (1990) (unpublished — not citable as precedent) ("The recitation of an additional advantage associated with doing what the prior art suggests does not lend patentability to an otherwise unpatentable invention."). In re Lintner, 458 F.2d 1013, 173 USPQ 560 (CCPA 1972) and In re Dillon, 919 F.2d 688, 16 USPQ2d 1897 (Fed. Cir. 1990) discussed in MPEP § 2144 are also pertinent to this issue. See MPEP § 716.02 - § 716.02(g) for a discussion of declaratory evidence alleging unexpected results. Applicant argued over motivation of modifying linear alkyl group with branched alkyl group of the cited prior art. PNG media_image14.png 378 996 media_image14.png Greyscale PNG media_image15.png 287 953 media_image15.png Greyscale PNG media_image16.png 777 687 media_image16.png Greyscale This is not found persuasive and the instant claims are obvious over the cited prior art. This is because (1) Since examples of species (R=Me and Et) and subgenus (R=1-6C alkyl) taught by the cited prior art are structurally similar to that claimed, it would have been obvious to a person of ordinary skill in the art to choose the claimed species or subgenus from the genus, based on the reasonable expectation that structurally similar species usually have similar properties. See, e.g., Dillon, 919 F.2d at 693, 696, 16 USPQ2d at 1901, 1904. See also Deuel, 51 F.3d at 1558, 34 USPQ2d at 1214. “Structural relationships may provide the requisite motivation or suggestion to modify known compounds to obtain new compounds. For example, a prior art compound may suggest its homologs because homologs often have similar properties and therefore chemists of ordinary skill would ordinarily contemplate making them to try to obtain compounds with improved properties.” Importantly, in this case, the cited prior art discloses homolog example (Ethyl) of the elected species (isopropyl) and also suggest that they have similar properties and therefore chemists of ordinary skill would contemplate making them to try to obtain compounds with improved properties. Further, a person of ordinary skill in the art would have been motivated to try different substituents on N atom and Si as suggested by the cited prior art to arrive at compounds useful in making ceramic material, fiber coating and binders. Thus, the cited prior art meets limitations of the instant claims; (2) both obviousness and motivation are not required under 103 and KSR as long as either obviousness to make compound or motivation to make compound is present. Applicant argued over unexpected results as provided in affidavit for compounds unrelated to compounds of the instant claims. Applicant presented new art and argued over compounds for linear vs branched compounds for their use such as in ALD, silicon-nitride films etc. PNG media_image17.png 776 694 media_image17.png Greyscale PNG media_image18.png 776 685 media_image18.png Greyscale PNG media_image18.png 776 685 media_image18.png Greyscale This is not found persuasive because contrary to applicant’s arguments and affidavit, perhydridocyclic silazane of formula I and perhydridosilazane of formula 4 does not share same structure. If these are same structure, applicant may amend the claim to perhydridocyclic silazane of formula I instead of perhydridosilazane of formula 4. Further, perhydridocyclic silazane of formula I is a cyclic compound and not an open chain perhydridosilazane of formula 4. Thus, again do not share same structure. Also, see paragraphs from the instant specification, as filed. PNG media_image8.png 595 820 media_image8.png Greyscale PNG media_image9.png 541 840 media_image9.png Greyscale PNG media_image10.png 647 836 media_image10.png Greyscale PNG media_image11.png 438 823 media_image11.png Greyscale Thus, the data presented in affidavit and argued is irrelevant to the instant claims and not persuasive. Just because two compounds contain Si-N bond do not make these compounds as same compounds. Having an ethyl group in two different compounds, does not make two different compounds as same compounds. For example, cyclic hexane and n-hexane are not same compounds. Additionally, none of the compounds of the cited prior are closely related to the compounds of the instant claims. Thus, discussion of these compounds related to differences of their use in ALD and Si-N films in regards to branched vs linear R groups is irrelevant to the instant claims. Further, the instant claims didn’t recite any limitation of ALD or Si-N films etc., thus applicant argument even using such properties is irrelevant to the instant claims. In other words, applicant is arguing over limitation and structures irrelevant to the instant claims. Importantly, applicant’s own invention as described in the specification provides that R as ethyl (linear, same as described in examples of the cited prior art) offers same advantages, volatility, pyrophoric properties etc., as the branched, such as isopropyl: PNG media_image19.png 604 776 media_image19.png Greyscale PNG media_image20.png 518 812 media_image20.png Greyscale Conclusion No Claim is allowed Any inquiry concerning this communication or earlier communications from the examiner should be directed to PANCHAM BAKSHI whose telephone number is (571)270-3463. The examiner can normally be reached M-Thu 7-4.30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Milligan Adam can be reached at 571-2707674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PANCHAM BAKSHI/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

May 15, 2023
Application Filed
Sep 13, 2024
Non-Final Rejection — §102, §103, §112
Mar 14, 2025
Response Filed
Mar 14, 2025
Response after Non-Final Action
Apr 29, 2025
Final Rejection — §102, §103, §112
Aug 04, 2025
Request for Continued Examination
Aug 05, 2025
Response after Non-Final Action
Oct 23, 2025
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595353
PLASTICIZER COMPOSITION AND RESIN COMPOSITION COMPRISING THE SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12594293
USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
2y 5m to grant Granted Apr 07, 2026
Patent 12590162
CANCER TREATMENT
2y 5m to grant Granted Mar 31, 2026
Patent 12565514
NUCLEIC ACID CONTAINING PERFLUOROALKYL GROUP, AND METHOD FOR ITS PRODUCTION
2y 5m to grant Granted Mar 03, 2026
Patent 12565466
SYNTHESIS AND USE OF PRECURSORS FOR VAPOR DEPOSITION OF TUNGSTEN CONTAINING THIN FILMS
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+30.4%)
2y 5m
Median Time to Grant
High
PTA Risk
Based on 1132 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month